About Innoviva (NASDAQ:INVA)
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
Industry, Sector and Symbol
Trailing P/E Ratio13.74
Forward P/E Ratio7.97
Sales & Book Value
Annual Sales$217.22 million
Price / Sales7.50
Cash Flow$1.51 per share
Price / Cash10.63
Book Value($2.38) per share
Price / Book-6.73
Net Income$134.14 million
Return on Equity-48.93%
Return on Assets35.25%
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported $0.50 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.49 by $0.01. The biotechnology company earned $69.52 million during the quarter, compared to the consensus estimate of $67.41 million. Innoviva had a net margin of 61.76% and a negative return on equity of 48.93%. Innoviva's revenue was up 59.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.22 EPS. View Innoviva's Earnings History.
When will Innoviva make its next earnings announcement?
Where is Innoviva's stock going? Where will Innoviva's stock price be in 2018?
5 equities research analysts have issued 1-year price objectives for Innoviva's shares. Their predictions range from $8.00 to $17.00. On average, they expect Innoviva's stock price to reach $13.40 in the next twelve months. View Analyst Ratings for Innoviva.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include ACADIA Pharmaceuticals (ACAD), Halozyme Therapeutics (HALO), Clovis Oncology (CLVS), Evotec (EVTCY), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Amicus Therapeutics (FOLD), China Biologic Products (CBPO), Ascendis Pharma A/S (ASND), AnaptysBio (ANAB), Emergent Biosolutions (EBS), arGEN-X BV (ARGX), Immunomedics (IMMU), Ultragenyx Pharmaceutical (RARE), Crispr Therapeutics (CRSP), Horizon Pharma (HZNP), The Medicines (MDCO) and Akorn (AKRX).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- William H. Waltrip, Independent Chairman of the Board (Age 78)
- Eric D'Esparbes, Interim Principal Executive Officer, Chief Financial Officer, Senior Vice President (Age 49)
- Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer (Age 59)
- George W. Bickerstaff III, Independent Director (Age 62)
- Barbara G. Duncan, Independent Director
- Catherine J. Friedman, Independent Director (Age 56)
- Odysseas D. Kostas M.D., Independent Director (Age 43)
- Patrick G. LePore, Independent Director (Age 62)
Has Innoviva been receiving favorable news coverage?
News stories about INVA stock have trended somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innoviva earned a news sentiment score of 0.14 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.00 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.45%), Renaissance Technologies LLC (1.41%), Goldman Sachs Group Inc. (0.87%), Geode Capital Management LLC (0.73%), Deutsche Bank AG (0.58%) and Victory Capital Management Inc. (0.55%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, James L Tyree, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.
Which institutional investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Deutsche Bank AG, BlackRock Inc., TIAA CREF Investment Management LLC, Two Sigma Investments LP, Goldman Sachs Group Inc., Spark Investment Management LLC and Foundry Partners LLC. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.
Which institutional investors are buying Innoviva stock?
INVA stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Renaissance Technologies LLC, Old Mutual Global Investors UK Ltd., LSV Asset Management, Guggenheim Capital LLC, Sawgrass Asset Management LLC, Arizona State Retirement System and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $16.01.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.62 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.11 on an earnings per share basis. Innoviva employs 12 workers across the globe.
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (INVA)MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Innoviva (NASDAQ:INVA) Earnings History and Estimates Chart
Innoviva (NASDAQ INVA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/8/2018||Q4 2017||$0.49||$0.50||$67.41 million||$69.52 million||View||Listen|
|10/25/2017||Q3 2017||$0.34||$0.21||$57.18 million||$48.64 million||View||N/A|
|7/26/2017||Q2 2017||$0.28||$0.30||$50.53 million||$58.60 million||View||N/A|
|4/27/2017||Q1 2017||$0.27||$0.15||$47.66 million||$40.50 million||View||N/A|
|2/9/2017||Q4 2016||$0.19||$0.22||$40.72 million||$43.60 million||View||Listen|
|10/27/2016||Q316||$0.19||$0.16||$38.71 million||$33.30 million||View||Listen|
|7/28/2016||Q216||$0.12||$0.17||$31.13 million||$32.47 million||View||Listen|
|4/28/2016||Q116||$0.09||$0.04||$28.61 million||$24.17 million||View||Listen|
|2/3/2016||Q415||$0.01||$0.04||$20.17 million||$22.80 million||View||N/A|
|10/28/2015||Q315||($0.03)||($0.04)||$15.23 million||$13.56 million||View||Listen|
|7/29/2015||Q2||($0.06)||($0.07)||$10.90 million||$10.70 million||View||Listen|
|5/6/2015||Q115||($0.08)||($0.09)||$8.64 million||$6.90 million||View||Listen|
|2/18/2015||Q414||($0.14)||($0.14)||$5.42 million||$7.30 million||View||N/A|
|10/30/2014||Q314||($0.15)||($0.19)||$5.06 million||$1.00 million||View||N/A|
|8/6/2014||Q214||($0.53)||($0.18)||$4.39 million||$0.93 million||View||N/A|
|5/6/2014||Q114||($0.53)||($0.62)||$4.52 million||$0.17 million||View||N/A|
|2/6/2014||Q413||($0.38)||($0.46)||$6.03 million||$1.60 million||View||N/A|
|10/24/2013||Q313||$0.69||($0.44)||$3.08 million||$0.44 million||View||N/A|
|7/25/2013||Q2 2013||($0.46)||($0.37)||$1.43 million||$1.33 million||View||N/A|
|4/25/2013||Q1 2013||($0.38)||($0.39)||$2.71 million||$1.34 million||View||N/A|
|2/12/2013||Q4 2012||($0.36)||($0.33)||$3.88 million||$5.80 million||View||N/A|
Innoviva (NASDAQ:INVA) Earnings Estimates
Current Year EPS Consensus Estimate: $2.01 EPS
Next Year EPS Consensus Estimate: $2.3 EPS
Innoviva (NASDAQ:INVA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Innoviva (NASDAQ INVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 74.99%
Innoviva (NASDAQ INVA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/21/2018||Eric Desparbes||Insider||Sell||5,378||$16.52||$88,844.56|| |
|2/21/2018||George B Abercrombie||VP||Sell||8,000||$16.51||$132,080.00|| |
|12/4/2017||Michael W Aguiar||Insider||Sell||12,022||$13.13||$157,848.86||980,907|| |
|11/21/2017||Eric Desparbes||CFO||Sell||15,285||$13.28||$202,984.80||337,027|| |
|11/21/2017||George B Abercrombie||VP||Sell||5,215||$13.26||$69,150.90||263,866|| |
|8/21/2017||Eric Desparbes||CFO||Sell||1,825||$12.20||$22,265.00||344,993|| |
|5/22/2017||Eric Desparbes||CFO||Sell||1,825||$11.85||$21,626.25||352,588|| |
|5/22/2017||Theodore J Jr. Witek||VP||Sell||7,815||$12.01||$93,858.15||251,968|| |
|2/21/2017||Eric Desparbes||CFO||Sell||1,825||$12.07||$22,027.75||356,121|| |
|11/22/2016||Theodore L Witek Jr||VP||Sell||3,700||$10.84||$40,108.00||157,131|| |
|11/21/2016||Eric Desparbes||CFO||Sell||1,800||$10.89||$19,602.00|| |
|8/22/2016||Eric Desparbes||CFO||Sell||3,700||$11.77||$43,549.00||239,893|| |
|5/18/2016||James L Tyree||Director||Sell||813||$10.47||$8,512.11||50,697|| |
|5/11/2015||Plc Glaxosmithkline||Major Shareholder||Buy||85,579||$1,369,260.00||$117,179,901,540.00|| |
|8/13/2014||Junning Lee||VP||Sell||53,424||$22.50||$1,202,040.00|| |
|8/12/2014||Bradford J Shafer||SVP||Sell||28,156||$22.13||$623,092.28|| |
|8/11/2014||Bradford J Shafer||SVP||Sell||27,108||$22.12||$599,628.96|| |
|9/12/2013||Rick Winningham||CEO||Sell||22,353||$40.03||$894,790.59||690,106|| |
|7/30/2013||Mathai Mammen||SVP||Sell||7,000||$36.51||$255,570.00|| |
|6/7/2013||Bradford J Shafer||SVP||Sell||31,038||$35.04||$1,087,571.52|| |
|5/29/2013||David L Brinkley||Insider||Sell||3,808||$35.01||$133,318.08|| |
|5/13/2013||David L Brinkley||Insider||Sell||16,129||$40.33||$650,482.57|| |
|8/7/2012||Michael W Aguiar||CFO||Sell||60,000||$27.04||$1,622,400.00|| |
Innoviva (NASDAQ INVA) News Headlines
|Innoviva (INVA) Upgraded to Buy by ValuEngine|
www.americanbankingnews.com - March 18 at 10:28 PM
|Innoviva (INVA) versus Teligent (TLGT) Head-To-Head Contrast|
www.americanbankingnews.com - March 15 at 3:46 PM
|Have Investors Priced In Innoviva Inc’s (NASDAQ:INVA) Growth?|
finance.yahoo.com - March 10 at 9:40 AM
|$73.83 Million in Sales Expected for Innoviva Inc (INVA) This Quarter|
www.americanbankingnews.com - March 5 at 1:48 AM
|Innoviva Inc (INVA) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - March 5 at 1:30 AM
|Zacks: Analysts Expect Innoviva Inc (INVA) Will Announce Earnings of $0.54 Per Share|
www.americanbankingnews.com - March 3 at 11:14 PM
|Contrasting Bristol-Myers Squibb (BMY) and Innoviva (INVA)|
www.americanbankingnews.com - February 28 at 1:30 AM
|Innoviva Inc (INVA) Shares Sold by Spark Investment Management LLC|
www.americanbankingnews.com - February 26 at 3:02 PM
|Innoviva Inc (INVA) Holdings Lifted by Smith Asset Management Group LP|
www.americanbankingnews.com - February 25 at 2:28 PM
|Innoviva Inc (INVA) Holdings Boosted by Systematic Financial Management LP|
www.americanbankingnews.com - February 25 at 11:38 AM
|Innoviva Inc (INVA) VP Sells $132,080.00 in Stock|
www.americanbankingnews.com - February 22 at 7:08 PM
|Eric Desparbes Sells 5,378 Shares of Innoviva Inc (INVA) Stock|
www.americanbankingnews.com - February 22 at 7:08 PM
|How Do Analysts See Innoviva Inc (NASDAQ:INVA) Performing In The Years Ahead?|
finance.yahoo.com - February 19 at 9:03 AM
|Innoviva (INVA) Upgraded to "B" by TheStreet|
www.americanbankingnews.com - February 18 at 9:22 PM
|Innoviva Inc (INVA) Expected to Post Quarterly Sales of $73.83 Million|
www.americanbankingnews.com - February 17 at 7:02 AM
|$0.52 EPS Expected for Innoviva Inc (INVA) This Quarter|
www.americanbankingnews.com - February 15 at 5:10 AM
|GSK Submits IMPACT Data To EU To Support Trelegy Ellipta's Expanded Labelling|
www.nasdaq.com - February 14 at 9:08 AM
|Drug company Innoviva settles with activist hedge fund Sarissa -sources|
finance.yahoo.com - February 13 at 9:07 AM
|Innoviva (INVA) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - February 11 at 9:36 AM
|Contrasting Innoviva (INVA) and Eyegate Pharmaceuticals (EYEG)|
www.americanbankingnews.com - February 10 at 1:24 PM
|Innoviva (INVA) Rating Reiterated by Stifel Nicolaus|
www.americanbankingnews.com - February 9 at 1:04 PM
|Innoviva beats Street 4Q forecasts|
finance.yahoo.com - February 9 at 9:11 AM
|Innoviva (INVA) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS|
www.americanbankingnews.com - February 8 at 9:46 PM
|Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - February 8 at 4:24 PM
|Innoviva Inc (INVA) Given Average Rating of "Hold" by Brokerages|
www.americanbankingnews.com - February 8 at 1:32 AM
|Innoviva (INVA) Downgraded to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - February 3 at 11:12 AM
|Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT|
finance.yahoo.com - February 2 at 4:37 PM
|Innoviva Inc (INVA) Expected to Post Quarterly Sales of $65.18 Million|
www.americanbankingnews.com - January 31 at 6:58 AM
|Innoviva (INVA) to Release Earnings on Wednesday|
www.americanbankingnews.com - January 31 at 2:28 AM
|Innoviva Inc (INVA) Expected to Announce Quarterly Sales of $66.75 Million|
www.americanbankingnews.com - January 14 at 9:58 AM
|Innoviva Inc (INVA) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - January 14 at 1:32 AM
| Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per Share|
www.americanbankingnews.com - January 12 at 9:30 AM
|Head-To-Head Analysis: Tetraphase Pharmaceuticals (TTPH) vs. Innoviva (INVA)|
www.americanbankingnews.com - January 10 at 8:02 AM
|Validea Joel Greenblatt Strategy Daily Upgrade Report - 1/5/2018 ... - Nasdaq|
www.nasdaq.com - January 5 at 8:01 AM
|Innoviva Sees RS Rating Rise To 74|
finance.yahoo.com - December 27 at 11:40 AM
|Zacks: Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per Share|
www.americanbankingnews.com - December 26 at 7:21 PM
|Innoviva Earns Relative Strength Rating Upgrade|
finance.yahoo.com - December 22 at 11:26 AM
|Innoviva (INVA) Upgraded at BidaskClub|
www.americanbankingnews.com - December 21 at 11:28 PM
|ETFs with exposure to Innoviva, Inc. : December 21, 2017|
finance.yahoo.com - December 21 at 3:24 PM
|Innoviva Inc (INVA) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - December 20 at 1:28 AM
|Amicus Therapeutics (FOLD) and Innoviva (INVA) Financial Contrast|
www.americanbankingnews.com - December 14 at 1:28 PM
|Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : December 12, 2017|
finance.yahoo.com - December 12 at 7:49 AM
|$66.75 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter|
www.americanbankingnews.com - December 11 at 1:00 PM
|Analyzing Innoviva (INVA) and Johnson & Johnson (JNJ)|
www.americanbankingnews.com - December 9 at 9:36 AM
|Innoviva, Inc. (INVA) Expected to Post Earnings of $0.45 Per Share|
www.americanbankingnews.com - December 9 at 5:30 AM
|Insider Selling: Innoviva, Inc. (INVA) Insider Sells 12,022 Shares of Stock|
www.americanbankingnews.com - December 5 at 7:14 PM
|ETFs with exposure to Innoviva, Inc. : December 1, 2017|
finance.yahoo.com - December 1 at 3:25 PM
|Innoviva, Inc. :INVA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017|
finance.yahoo.com - November 30 at 11:58 AM
|Comparing Innoviva (INVA) and Its Rivals|
www.americanbankingnews.com - November 27 at 5:22 PM
|Analyzing Innoviva (INVA) & Its Competitors|
www.americanbankingnews.com - November 25 at 11:04 PM
Innoviva (NASDAQ:INVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Innoviva (NASDAQ:INVA) Income Statement, Balance Sheet and Cash Flow Statement
Innoviva (NASDAQ INVA) Stock Chart for Wednesday, March, 21, 2018